Cellectis

Cellectis is a gene-editing company employing its core proprietary technologies to develop products in the field of immuno-oncology. UCART19 is Co.'s lead product. UCART19 is an engineered T-cell product which drives its ability to target and kill CD19-bearing cells, such as B-cell malignancies. Co. is also developing wholly-owned product candidates UCART123, UCARTCS1 and UCART38, which are in various stages of development. UCART 123, UCARTCS1 and UCART38 are engineered T-cell products that bear CARs that seek to kill cells expressing targets CD123, CS1 and CD38, respectively, which are found in other hematologic tumors, such as acute myeloid leukemia, or AML, and multiple myeloma, or MM.
  • TickerALCLS
  • ISINFR0010425595
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Cellectis: 1 director bought

A director at Cellectis bought 1,440 shares at 16.453EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board mem...

Valérie GASTALDY

Short term view - CELLECTIS : The background trend is clearly bullish.

The background trend is clearly bullish. Prices are still making progress. The following targets are at €26.88 and €29.80. The trend would be invalidated below the support at €18.32.

Valérie GASTALDY

Analyse court terme - CELLECTIS : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Les cours progressent toujours. Les objectifs suivants sont à 26,88 € et 29,80 €. La tendance serait invalidée sous le support à 18,32 €.

Louis AZAIS

Analyse moyen terme - CELLECTIS : Les cours progressent toujours.

La tendance de fond est clairement orientée à la hausse. Les cours progressent toujours. Les objectifs suivants sont à 30,00 € et 41,77 €. La tendance serait invalidée sous le support à 14,60 €.

Louis AZAIS

Medium term view - CELLECTIS : Prices are still making progress.

The background trend is clearly bullish. Prices are still making progress. The following targets are at €30.00 and €41.77. The trend would be invalidated below the support at €14.60.

Cellectis: 1 director bought

A director at Cellectis bought 1,440 shares at 16.453EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board mem...

Martial Descoutures ...
  • Oussema Denguir

Cellectis : Agreement with Servier amended

>Amendment to its licence agreement with Servier - Cellectis has just announced an amendment to its initial agreement with Servier. This will allow Servier to obtain an exclusive worldwide license for the development and subsequent marketing of all products targeting CD19 (including ALLO-501A). In parallel, Cellectis will regain control over its five developments initially licensed to Servier but for which the targets had never been disclosed. On the financial s...

Martial Descoutures ...
  • Oussema Denguir

Cellectis : Une modification de son accord avec Servier

>Avenant à son accord de licence avec Servier - Cellectis vient d’annoncer avoir procédé à un avenant sur son accord initial avec Servier. Celui-ci permettra à Servier d’obtenir une licence mondiale exclusive pour le développement suivi de la commercialisation de l’ensemble des produits ciblant CD19 (y compris ALLO-501A). En parallèle, Cellectis reprendra la main sur ses cinq développements donnés initialement sous licence à Servier mais dont les cibles n’avaient jama...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior